NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebralSeptember 8, 2026Read article
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 8, 2026Read article
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsSeptember 8, 2026Read article
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of DirectorsSeptember 8, 2026Read article
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionJune 24, 2026Read article
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026Read article
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsJune 24, 2026Read article
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 24, 2026Read article
Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsJune 24, 2026Read article
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 24, 2026Read article
